Translational Science
Tumor heterogeneity represents a significant barrier to improving HCC patient outcome and poses a challenge for the establishment of robust HCC classification, making treatment extremely difficult. Consequently, the ability to discriminate patients with greater homogeneity and clinically relevant therapeutic targets will help guide treatments to improve patient outcome. We have developed a robust 20-NELFE dependent MYC (NDMPOS) gene signature, which reflects the biological characteristics of HCC. We are interested in utilizing genome wide CRISPR/Cas9 screens to identify therapeutics for this specific subtype. We also identified a NELFE single nucleotide polymorphism (SNP) that affects NELFE splicing. Currently, we are investigating its protective role in HCC.